. 2010 May 7;18(8):1007–1021. doi: 10.1007/s00520-010-0873-2

Table 6.

Summary of fluoride studies (5)

Author	Dx	Tx	Study type	Time of assessment	Final N/intervention 1	Final N/intervention 2	Final N/intervention 3
Al Joburi et al. 1995 [43]	H&N^a	RT^b	RCT^c	Post-RT^b	N = 69	N = 56	N = 18
			RCT^c	Patients recalled at intervals ranging 4 to 6 months, all patients reexamined after one year during recall appointments	Sodium fluoride gel in custom trays daily for 5 min for 3 months	Brush with stannous fluoride gel instead of dentifrice	Noncompliant with fluoride therapy
			Single blind (operator)		Reminineralizing mouth rinse twice a day for next 3 months
			Single blind (operator)		Continued use of regular dentifrice

Chambers et al. 2007 [46]	H&N^a	RT^b	RCT^c	3 months post-RT^b	Placement of IRFS retainers on bilateral maxillary molars for all patients and all used 1,100 ppm toothpaste twice daily, oral hygiene instructions
			RCT^c	3 months post-RT^b	N = 9	N = 11
			Single blind (operator)	At placement of intraoral fluoride releasing system (IRFS) retainers, at 4, 8, 12, 24, 36, and 48 weeks	Sustained release fluoride tablet replaced every 3 months	0.4% Stannous fluoride gel in custom trays daily for 10 min
			Single blind (operator)		Sodium fluoride/hydroxy ethyl methacrylate/methyly methacrylate (50:50 ratio of HEMA/MMA)	0.4% Stannous fluoride gel in custom trays daily for 10 min

Meurman et al. 1991 [47]	Hodgkin's and non-Hodgkin's disease	CT^d	RCT^c	During combination CT^d	All patients went through a rinse period with 0.05% sodium fluoride solution from weeks 2 to 4
			Double-blind cross-over study	Assessed prior to anticancer treatment, and before and after each period of rinsing with different type of mouthwash	In addition, patients in the amine-stannous fluoride group also had 0.05% sodium fluoride solution from weeks 6 to 8
					N = 51 (self control)	N = 51 (self control)
					0.12% Chlorhexidine (CHLX) rinse	0.025% Amine-stannous fluoride mouth rinse

Meyerowitz et al. 1998 [45]	Not specified (assumed H&N^a)	H&N^a RT	RCT^c	Post-RT^b (completed >3 months before study)	N = 13	N = 10
Meyerowitz et al. 1998 [45]	Not specified (assumed H&N^a)	H&N^a RT	Single blind (operator)	Assessments at baseline (before placement of IFRS), 1, 2, 3, 4, 5, and 6 (end of study) months	Intraoral fluoride releasing system (IFRS), fluoride pellet: sodium fluoride/hydroxy ethyl methacrylate/methyly methacrylate (50:50 ratio of HEMA/MMA)	1.1% Neutral sodium fluoride in custom trays, 5 min daily

Spak et al. 1994 [44]	H&N^a	RT^b	RCT ^c	Assessed immediate prior to RT^b, 6 and at 12 months after RT^b	N = 19	N = 18
Spak et al. 1994 [44]	H&N^a	RT^b	Double blind		0.42% Fluoride gel daily from start of radiation until 2 weeks after end of radiation, then daily use of 1.23% fluoride gel for 4 weeks. Thereafter, switched to 0.42% fluoride gel and use until 1 year after baseline exam	0.42% Fluoride gel daily from start of radiation until 1 year after baseline exam

^aHead and neck

^bRadiation

^cRandomized control trial

^dChemotherapy